rituximab Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Roche rituximab
    Pharmacokinetics. After intravenous administration of 111 MBq 89 <t>Zr-rituximab,</t> blood samples were obtained from the arm opposite the infusion side 10 min, 1 and 2 h, and then 1, 3 and 6 days after infusion. At each time-point, 89 Zr disintegration counts/unit volume were measured using a calibrated γ-well counter corrected for 89 Zr physical decay. a Clearance half-life of 89 Zr-rituximab with and without predosing. b , c Blood concentration of 89 Zr-rituximab expressed as percentages of the initial 10-min value in ( b ) patients 1 and 2 with preserved circulating CD20+ lymphocytes and ( c ) patients 3, 4 and 5 with B-cell depletion
    Rituximab, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rituximab/product/Roche
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rituximab - by Bioz Stars, 2021-07
    86/100 stars
      Buy from Supplier

    86
    Genentech rituximab
    <t>Rituximab</t> X Placebo. Meta-analysis of the outcome Schimer test at week 24.
    Rituximab, supplied by Genentech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rituximab/product/Genentech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rituximab - by Bioz Stars, 2021-07
    86/100 stars
      Buy from Supplier

    86
    Biogen Inc rituximab
    Comparison 4 Treatment of first rejection (B cell): <t>rituximab</t> + steroids versus steroids alone, Outcome 3 Graft loss or death with a functioning graft within 12 months.
    Rituximab, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rituximab/product/Biogen Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rituximab - by Bioz Stars, 2021-07
    86/100 stars
      Buy from Supplier

    86
    Roche rituximab rp
    Serum concentrations over time by treatment (week 4–12) in the subset of patients who agreed to the optional PK testing. Note: This graph represents PK results from the 45 patients treated with ABP 798 and the 41 patients treated with <t>rituximab</t> RP who agreed to the optional PK sampling. The sample sizes for each visit (ABP 798 vs rituximab) were as follows: week 4 predose (44 vs 39), week 4 post-dose (36 vs 32), week 5 (38 vs 37), and week 12 predose (44 vs 41). PK pharmacokinetic, RP reference product
    Rituximab Rp, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rituximab rp/product/Roche
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rituximab rp - by Bioz Stars, 2021-07
    86/100 stars
      Buy from Supplier

    N/A
    Rituxan is a genetically engineered chimeric murine human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes The antibody is an IgG1
      Buy from Supplier

    N/A
    The Rituximab Antibody 109H9 06 from Novus Biologicals is a mouse monoclonal antibody to Rituximab This antibody reacts with human The Rituximab Antibody 109H9 06 has been validated for the
      Buy from Supplier

    N/A
    The Rituximab Antibody 108F11 02 from Novus Biologicals is a mouse monoclonal antibody to Rituximab This antibody reacts with human The Rituximab Antibody 108F11 02 has been validated for the
      Buy from Supplier

    N/A
    The CD20 Antibody 10F381 rituximab from Novus Biologicals is a rabbit monoclonal antibody to CD20 This antibody reacts with human The CD20 Antibody 10F381 rituximab has been validated for the
      Buy from Supplier

    Image Search Results


    Pharmacokinetics. After intravenous administration of 111 MBq 89 Zr-rituximab, blood samples were obtained from the arm opposite the infusion side 10 min, 1 and 2 h, and then 1, 3 and 6 days after infusion. At each time-point, 89 Zr disintegration counts/unit volume were measured using a calibrated γ-well counter corrected for 89 Zr physical decay. a Clearance half-life of 89 Zr-rituximab with and without predosing. b , c Blood concentration of 89 Zr-rituximab expressed as percentages of the initial 10-min value in ( b ) patients 1 and 2 with preserved circulating CD20+ lymphocytes and ( c ) patients 3, 4 and 5 with B-cell depletion

    Journal: European Journal of Nuclear Medicine and Molecular Imaging

    Article Title: Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab

    doi: 10.1007/s00259-015-3025-6

    Figure Lengend Snippet: Pharmacokinetics. After intravenous administration of 111 MBq 89 Zr-rituximab, blood samples were obtained from the arm opposite the infusion side 10 min, 1 and 2 h, and then 1, 3 and 6 days after infusion. At each time-point, 89 Zr disintegration counts/unit volume were measured using a calibrated γ-well counter corrected for 89 Zr physical decay. a Clearance half-life of 89 Zr-rituximab with and without predosing. b , c Blood concentration of 89 Zr-rituximab expressed as percentages of the initial 10-min value in ( b ) patients 1 and 2 with preserved circulating CD20+ lymphocytes and ( c ) patients 3, 4 and 5 with B-cell depletion

    Article Snippet: Rituximab (Mabthera®; Roche, Basel, Switzerland) was labelled with 89 Zr starting from the chelate, TFP-N-sucDf-Fe, as described previously [ ].

    Techniques: Concentration Assay

    Influence of a preload of unlabelled rituximab on the radiation dose to the liver

    Journal: European Journal of Nuclear Medicine and Molecular Imaging

    Article Title: Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab

    doi: 10.1007/s00259-015-3025-6

    Figure Lengend Snippet: Influence of a preload of unlabelled rituximab on the radiation dose to the liver

    Article Snippet: Rituximab (Mabthera®; Roche, Basel, Switzerland) was labelled with 89 Zr starting from the chelate, TFP-N-sucDf-Fe, as described previously [ ].

    Techniques:

    18 F-FDG PET/CT and 89 Zr-rituximab immuno-PET/CT images in patient 2 obtained 6 days after injection with and without a preload of unlabelled rituximab show lower tracer uptake in involved lymph nodes with the preload ( white arrows ), but higher uptake in less accessible visceral lesions (oesophagus and stomach; blue arrows ) resulting in better tumour targeting

    Journal: European Journal of Nuclear Medicine and Molecular Imaging

    Article Title: Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab

    doi: 10.1007/s00259-015-3025-6

    Figure Lengend Snippet: 18 F-FDG PET/CT and 89 Zr-rituximab immuno-PET/CT images in patient 2 obtained 6 days after injection with and without a preload of unlabelled rituximab show lower tracer uptake in involved lymph nodes with the preload ( white arrows ), but higher uptake in less accessible visceral lesions (oesophagus and stomach; blue arrows ) resulting in better tumour targeting

    Article Snippet: Rituximab (Mabthera®; Roche, Basel, Switzerland) was labelled with 89 Zr starting from the chelate, TFP-N-sucDf-Fe, as described previously [ ].

    Techniques: Positron Emission Tomography, Injection

    18 F-FDG PET and 89 Zr-rituximab immuno-PET images in patient 1 obtained 1 h after injection and 6 days after injection without a preload of unlabelled rituximab and 6 days after injection with a preload of unlabelled rituximab show higher uptake in the involved lymph node with the preload as a result of a higher residence time of the tracer in the blood circulation

    Journal: European Journal of Nuclear Medicine and Molecular Imaging

    Article Title: Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab

    doi: 10.1007/s00259-015-3025-6

    Figure Lengend Snippet: 18 F-FDG PET and 89 Zr-rituximab immuno-PET images in patient 1 obtained 1 h after injection and 6 days after injection without a preload of unlabelled rituximab and 6 days after injection with a preload of unlabelled rituximab show higher uptake in the involved lymph node with the preload as a result of a higher residence time of the tracer in the blood circulation

    Article Snippet: Rituximab (Mabthera®; Roche, Basel, Switzerland) was labelled with 89 Zr starting from the chelate, TFP-N-sucDf-Fe, as described previously [ ].

    Techniques: Positron Emission Tomography, Injection

    Comparison of lesion uptake (SUV max ) without and with a preload of unlabelled rituximab

    Journal: European Journal of Nuclear Medicine and Molecular Imaging

    Article Title: Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab

    doi: 10.1007/s00259-015-3025-6

    Figure Lengend Snippet: Comparison of lesion uptake (SUV max ) without and with a preload of unlabelled rituximab

    Article Snippet: Rituximab (Mabthera®; Roche, Basel, Switzerland) was labelled with 89 Zr starting from the chelate, TFP-N-sucDf-Fe, as described previously [ ].

    Techniques:

    89 Zr-rituximab immuno-PET/CT images in patient 4 (with CD20+ B-cell depletion) obtained 6 days after injection without and with a preload of unlabelled rituximab show consistently better tumour targeting without the preload

    Journal: European Journal of Nuclear Medicine and Molecular Imaging

    Article Title: Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab

    doi: 10.1007/s00259-015-3025-6

    Figure Lengend Snippet: 89 Zr-rituximab immuno-PET/CT images in patient 4 (with CD20+ B-cell depletion) obtained 6 days after injection without and with a preload of unlabelled rituximab show consistently better tumour targeting without the preload

    Article Snippet: Rituximab (Mabthera®; Roche, Basel, Switzerland) was labelled with 89 Zr starting from the chelate, TFP-N-sucDf-Fe, as described previously [ ].

    Techniques: Positron Emission Tomography, Injection

    Whole-body dosimetry of 90 Y-rituximab with and without a preload of unlabelled (“cold”) rituximab antibodies

    Journal: European Journal of Nuclear Medicine and Molecular Imaging

    Article Title: Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab

    doi: 10.1007/s00259-015-3025-6

    Figure Lengend Snippet: Whole-body dosimetry of 90 Y-rituximab with and without a preload of unlabelled (“cold”) rituximab antibodies

    Article Snippet: Rituximab (Mabthera®; Roche, Basel, Switzerland) was labelled with 89 Zr starting from the chelate, TFP-N-sucDf-Fe, as described previously [ ].

    Techniques:

    Influence of a preload of unlabelled rituximab on the radiation dose to the bone marrow

    Journal: European Journal of Nuclear Medicine and Molecular Imaging

    Article Title: Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab

    doi: 10.1007/s00259-015-3025-6

    Figure Lengend Snippet: Influence of a preload of unlabelled rituximab on the radiation dose to the bone marrow

    Article Snippet: Rituximab (Mabthera®; Roche, Basel, Switzerland) was labelled with 89 Zr starting from the chelate, TFP-N-sucDf-Fe, as described previously [ ].

    Techniques:

    89 Zr-rituximab immuno-PET images obtained 6 days after injection in a patient (patient 2; anterior view) with a preserved amount of circulating CD20+ lymphocytes and a patient (patient 3; posterior view) with B-cell depletion

    Journal: European Journal of Nuclear Medicine and Molecular Imaging

    Article Title: Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab

    doi: 10.1007/s00259-015-3025-6

    Figure Lengend Snippet: 89 Zr-rituximab immuno-PET images obtained 6 days after injection in a patient (patient 2; anterior view) with a preserved amount of circulating CD20+ lymphocytes and a patient (patient 3; posterior view) with B-cell depletion

    Article Snippet: Rituximab (Mabthera®; Roche, Basel, Switzerland) was labelled with 89 Zr starting from the chelate, TFP-N-sucDf-Fe, as described previously [ ].

    Techniques: Positron Emission Tomography, Injection

    Rituximab X Placebo. Meta-analysis of the outcome Schimer test at week 24.

    Journal: PLoS ONE

    Article Title: Rituximab Effectiveness and Safety for Treating Primary Sjögren’s Syndrome (pSS): Systematic Review and Meta-Analysis

    doi: 10.1371/journal.pone.0150749

    Figure Lengend Snippet: Rituximab X Placebo. Meta-analysis of the outcome Schimer test at week 24.

    Article Snippet: Search strategy We developed search strategies including the following terms and synonyms: “rituximab”, “CD20 antibody rituximab”, “Mabthera”, “Roche brand of rituximab”, “rituxan”, “Hoffmann-La Roche brand of rituximab”, “IDEC brand of rituximab”, “Genentech brand of rituximab”, “IDEC-C2B8 antibody”, “IDEC-C2B8”, “Sjogren's Syndrome”, “Sjogren Syndrome”, “Sjogrens Syndrome”, “Syndrome Sjogren's”, “Sicca Syndrome” and “Syndrome Sicca”.

    Techniques:

    Rituximab X Placebo. Meta-analysis of the outcome fatigue VAS 30% improvement at week 24.

    Journal: PLoS ONE

    Article Title: Rituximab Effectiveness and Safety for Treating Primary Sjögren’s Syndrome (pSS): Systematic Review and Meta-Analysis

    doi: 10.1371/journal.pone.0150749

    Figure Lengend Snippet: Rituximab X Placebo. Meta-analysis of the outcome fatigue VAS 30% improvement at week 24.

    Article Snippet: Search strategy We developed search strategies including the following terms and synonyms: “rituximab”, “CD20 antibody rituximab”, “Mabthera”, “Roche brand of rituximab”, “rituxan”, “Hoffmann-La Roche brand of rituximab”, “IDEC brand of rituximab”, “Genentech brand of rituximab”, “IDEC-C2B8 antibody”, “IDEC-C2B8”, “Sjogren's Syndrome”, “Sjogren Syndrome”, “Sjogrens Syndrome”, “Syndrome Sjogren's”, “Sicca Syndrome” and “Syndrome Sicca”.

    Techniques:

    Rituximab X Placebo. Meta-analysis of the outcome SF-36 mental component summary at week 24.

    Journal: PLoS ONE

    Article Title: Rituximab Effectiveness and Safety for Treating Primary Sjögren’s Syndrome (pSS): Systematic Review and Meta-Analysis

    doi: 10.1371/journal.pone.0150749

    Figure Lengend Snippet: Rituximab X Placebo. Meta-analysis of the outcome SF-36 mental component summary at week 24.

    Article Snippet: Search strategy We developed search strategies including the following terms and synonyms: “rituximab”, “CD20 antibody rituximab”, “Mabthera”, “Roche brand of rituximab”, “rituxan”, “Hoffmann-La Roche brand of rituximab”, “IDEC brand of rituximab”, “Genentech brand of rituximab”, “IDEC-C2B8 antibody”, “IDEC-C2B8”, “Sjogren's Syndrome”, “Sjogren Syndrome”, “Sjogrens Syndrome”, “Syndrome Sjogren's”, “Sicca Syndrome” and “Syndrome Sicca”.

    Techniques:

    Rituximab X Placebo. Meta-analysis of the outcome oral dryness (VAS) at week 24.

    Journal: PLoS ONE

    Article Title: Rituximab Effectiveness and Safety for Treating Primary Sjögren’s Syndrome (pSS): Systematic Review and Meta-Analysis

    doi: 10.1371/journal.pone.0150749

    Figure Lengend Snippet: Rituximab X Placebo. Meta-analysis of the outcome oral dryness (VAS) at week 24.

    Article Snippet: Search strategy We developed search strategies including the following terms and synonyms: “rituximab”, “CD20 antibody rituximab”, “Mabthera”, “Roche brand of rituximab”, “rituxan”, “Hoffmann-La Roche brand of rituximab”, “IDEC brand of rituximab”, “Genentech brand of rituximab”, “IDEC-C2B8 antibody”, “IDEC-C2B8”, “Sjogren's Syndrome”, “Sjogren Syndrome”, “Sjogrens Syndrome”, “Syndrome Sjogren's”, “Sicca Syndrome” and “Syndrome Sicca”.

    Techniques:

    Rituximab X Placebo. Meta-analysis of the outcome disease activity assessed through the ESSDAI at week 24.

    Journal: PLoS ONE

    Article Title: Rituximab Effectiveness and Safety for Treating Primary Sjögren’s Syndrome (pSS): Systematic Review and Meta-Analysis

    doi: 10.1371/journal.pone.0150749

    Figure Lengend Snippet: Rituximab X Placebo. Meta-analysis of the outcome disease activity assessed through the ESSDAI at week 24.

    Article Snippet: Search strategy We developed search strategies including the following terms and synonyms: “rituximab”, “CD20 antibody rituximab”, “Mabthera”, “Roche brand of rituximab”, “rituxan”, “Hoffmann-La Roche brand of rituximab”, “IDEC brand of rituximab”, “Genentech brand of rituximab”, “IDEC-C2B8 antibody”, “IDEC-C2B8”, “Sjogren's Syndrome”, “Sjogren Syndrome”, “Sjogrens Syndrome”, “Syndrome Sjogren's”, “Sicca Syndrome” and “Syndrome Sicca”.

    Techniques: Activity Assay

    Rituximab X Placebo. Meta-analysis of the outcome salivary flow rate at week 24.

    Journal: PLoS ONE

    Article Title: Rituximab Effectiveness and Safety for Treating Primary Sjögren’s Syndrome (pSS): Systematic Review and Meta-Analysis

    doi: 10.1371/journal.pone.0150749

    Figure Lengend Snippet: Rituximab X Placebo. Meta-analysis of the outcome salivary flow rate at week 24.

    Article Snippet: Search strategy We developed search strategies including the following terms and synonyms: “rituximab”, “CD20 antibody rituximab”, “Mabthera”, “Roche brand of rituximab”, “rituxan”, “Hoffmann-La Roche brand of rituximab”, “IDEC brand of rituximab”, “Genentech brand of rituximab”, “IDEC-C2B8 antibody”, “IDEC-C2B8”, “Sjogren's Syndrome”, “Sjogren Syndrome”, “Sjogrens Syndrome”, “Syndrome Sjogren's”, “Sicca Syndrome” and “Syndrome Sicca”.

    Techniques: Flow Cytometry

    Rituximab X Placebo. Meta-analysis of the outcome serious adverse events at week 24.

    Journal: PLoS ONE

    Article Title: Rituximab Effectiveness and Safety for Treating Primary Sjögren’s Syndrome (pSS): Systematic Review and Meta-Analysis

    doi: 10.1371/journal.pone.0150749

    Figure Lengend Snippet: Rituximab X Placebo. Meta-analysis of the outcome serious adverse events at week 24.

    Article Snippet: Search strategy We developed search strategies including the following terms and synonyms: “rituximab”, “CD20 antibody rituximab”, “Mabthera”, “Roche brand of rituximab”, “rituxan”, “Hoffmann-La Roche brand of rituximab”, “IDEC brand of rituximab”, “Genentech brand of rituximab”, “IDEC-C2B8 antibody”, “IDEC-C2B8”, “Sjogren's Syndrome”, “Sjogren Syndrome”, “Sjogrens Syndrome”, “Syndrome Sjogren's”, “Sicca Syndrome” and “Syndrome Sicca”.

    Techniques:

    Comparison 4 Treatment of first rejection (B cell): rituximab + steroids versus steroids alone, Outcome 3 Graft loss or death with a functioning graft within 12 months.

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients

    doi: 10.1002/14651858.CD004756.pub4

    Figure Lengend Snippet: Comparison 4 Treatment of first rejection (B cell): rituximab + steroids versus steroids alone, Outcome 3 Graft loss or death with a functioning graft within 12 months.

    Article Snippet: Two studies looking at humoral rejection using rituximab; (20 participants) compared rituximab with steroid‐to‐steroid alone, and (38 participants) compared rituximab with placebo. used anti‐CD 20 rituximab manufactured by BIOGEN‐IDEC Pharmaceuticals and Genentech Inc.

    Techniques:

    Comparison 4 Treatment of first rejection (B cell): rituximab + steroids versus steroids alone, Outcome 4 Death within 12 months.

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients

    doi: 10.1002/14651858.CD004756.pub4

    Figure Lengend Snippet: Comparison 4 Treatment of first rejection (B cell): rituximab + steroids versus steroids alone, Outcome 4 Death within 12 months.

    Article Snippet: Two studies looking at humoral rejection using rituximab; (20 participants) compared rituximab with steroid‐to‐steroid alone, and (38 participants) compared rituximab with placebo. used anti‐CD 20 rituximab manufactured by BIOGEN‐IDEC Pharmaceuticals and Genentech Inc.

    Techniques:

    Comparison 4 Treatment of first rejection (B cell): rituximab + steroids versus steroids alone, Outcome 2 Additional treatment required.

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients

    doi: 10.1002/14651858.CD004756.pub4

    Figure Lengend Snippet: Comparison 4 Treatment of first rejection (B cell): rituximab + steroids versus steroids alone, Outcome 2 Additional treatment required.

    Article Snippet: Two studies looking at humoral rejection using rituximab; (20 participants) compared rituximab with steroid‐to‐steroid alone, and (38 participants) compared rituximab with placebo. used anti‐CD 20 rituximab manufactured by BIOGEN‐IDEC Pharmaceuticals and Genentech Inc.

    Techniques:

    Comparison 4 Treatment of first rejection (B cell): rituximab + steroids versus steroids alone, Outcome 1 Failure of reversal of acute rejection.

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients

    doi: 10.1002/14651858.CD004756.pub4

    Figure Lengend Snippet: Comparison 4 Treatment of first rejection (B cell): rituximab + steroids versus steroids alone, Outcome 1 Failure of reversal of acute rejection.

    Article Snippet: Two studies looking at humoral rejection using rituximab; (20 participants) compared rituximab with steroid‐to‐steroid alone, and (38 participants) compared rituximab with placebo. used anti‐CD 20 rituximab manufactured by BIOGEN‐IDEC Pharmaceuticals and Genentech Inc.

    Techniques:

    Comparison 4 Treatment of first rejection (B cell): rituximab + steroids versus steroids alone, Outcome 5 Treatment adverse events.

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients

    doi: 10.1002/14651858.CD004756.pub4

    Figure Lengend Snippet: Comparison 4 Treatment of first rejection (B cell): rituximab + steroids versus steroids alone, Outcome 5 Treatment adverse events.

    Article Snippet: Two studies looking at humoral rejection using rituximab; (20 participants) compared rituximab with steroid‐to‐steroid alone, and (38 participants) compared rituximab with placebo. used anti‐CD 20 rituximab manufactured by BIOGEN‐IDEC Pharmaceuticals and Genentech Inc.

    Techniques:

    Serum concentrations over time by treatment (week 4–12) in the subset of patients who agreed to the optional PK testing. Note: This graph represents PK results from the 45 patients treated with ABP 798 and the 41 patients treated with rituximab RP who agreed to the optional PK sampling. The sample sizes for each visit (ABP 798 vs rituximab) were as follows: week 4 predose (44 vs 39), week 4 post-dose (36 vs 32), week 5 (38 vs 37), and week 12 predose (44 vs 41). PK pharmacokinetic, RP reference product

    Journal: Targeted Oncology

    Article Title: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product

    doi: 10.1007/s11523-020-00748-4

    Figure Lengend Snippet: Serum concentrations over time by treatment (week 4–12) in the subset of patients who agreed to the optional PK testing. Note: This graph represents PK results from the 45 patients treated with ABP 798 and the 41 patients treated with rituximab RP who agreed to the optional PK sampling. The sample sizes for each visit (ABP 798 vs rituximab) were as follows: week 4 predose (44 vs 39), week 4 post-dose (36 vs 32), week 5 (38 vs 37), and week 12 predose (44 vs 41). PK pharmacokinetic, RP reference product

    Article Snippet: Disease stage at screening was stage IV in 74 patients (28.9%) (ABP 798: 34 [26.6%]; rituximab RP: 40 [31.3%]), stage III in 119 patients (46.6%) (ABP 798: 60 [46.9%]; rituximab RP: 59 [46.1%]), stage II in 63 patients (24.7%) (ABP 798: 34 [26.6%]; rituximab RP: 29 [22.7%]), and stage I in no patients (0.0%).

    Techniques: Sampling